MRKR
What one share of Marker Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s Multi Antigen Recognizing (“MAR”)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications.
Marker Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.47 |
|---|---|
| Cash and investments | $0.68 |
| Book value | $0.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.19 | −$11.62 | $0.00 | −$8.93 | — | $3.45 |
| 2018 | $0.11 | −$77.50 | $0.08 | −$7.66 | — | — |
| 2019 | $0.05 | −$4.70 | $0.08 | −$4.09 | — | $9.65 |
| 2020 | $0.11 | −$6.10 | — | −$4.26 | — | $5.39 |
| 2021 | $0.00 | −$5.47 | — | −$3.57 | — | $5.30 |
| 2022 | $0.42 | −$3.58 | — | −$3.23 | — | $2.33 |
| 2023 | $0.38 | −$0.94 | — | −$1.87 | — | $1.58 |
| 2024 | $0.73 | −$1.20 | — | −$1.21 | — | $1.73 |
| 2025 | $0.23 | −$0.79 | — | −$0.78 | — | $1.01 |